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ABSTRACT Compartmentalisation of the respiratory tract microbiota in patients with different chronic
obstructive pulmonary disease (COPD) severity degrees needs to be systematically investigated. In
addition, it is unknown if the inflammatory and emphysematous milieux in patients with COPD are
associated with changes in the respiratory tract microbiota and host macrophage gene expression.
We performed a cross-sectional study to compare non-COPD controls (n=10) to COPD patients (n=32)
with different disease severity degrees. Samples (n=187) were obtained from different sites of the upper
and lower respiratory tract. Microbiota analyses were performed by 16S ribosomal RNA gene sequencing
and host gene expression analyses by quantitative real-time PCR of distinct markers of bronchoalveolar
lavage cells.
Overall, the microbial communities of severe COPD (Global Initiative for Chronic Obstructive Lung
Disease (GOLD) grade 3/4) patients clustered significantly differently to controls and less severe COPD
(GOLD 1/2) patients (permutational multivariate ANOVA (MANOVA), p=0.001). However, we could not
detect significant associations between the different sampling sites in the lower airways. In addition, the
chosen set of host gene expression markers significantly separated COPD GOLD 3/4 patients, and we
found correlations between the composition of the microbiota and the host data.
In conclusion, this study demonstrates associations between host gene expression and microbiota
profiles that may influence the course of COPD.
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Introduction
It has been shown that patients with chronic obstructive pulmonary disease (COPD) not only suffer from
infections that lead to exacerbations but, in general, show a disordered lung microbiota composition
compared to healthy controls [1–4]. Nevertheless, data from stable COPD patients are still scarce and it is
not yet fully understood whether there is a heterogeneity of the microbiota along the respiratory tract of
patients with COPD, although microanatomic differences in bacterial communities within the same lung
of subjects with advanced COPD have been suggested [2, 5]. Closely linked to the disordering of the
microbiota is the change in the host immune status of patients with COPD. Specifically, innate airway
immune cells, primarily macrophages, which are markedly increased in the airways of COPD patients, play
a key role in the inflammatory processes in COPD [6]. Macrophages are a heterogeneous cell population
endowed with plasticity in different disease states and extremes in polarisation, ranging from pro- to
anti-inflammatory phenotypes [7]. In mice, prototypic M1- and M2-like activated macrophages may be
distinguished, where M1-like macrophages are characterised as proinflammatory and M2-like macrophages
as anti-inflammatory with release of interleukin (IL)-10 and phagocytic activity [8]. It has been suggested
that proinflammatory macrophages predominate in COPD patients [6, 9], but the contribution of distinct
phenotypes and the environmental factors that determine these phenotypes are still largely unknown.
In this study, we performed a cross-sectional analysis of patients (n=32) with different COPD lung
functional severity degrees (grouped into Global Initiative for Chronic Obstructive Lung Disease (GOLD)
grades 1–4, www.goldcopd.org), which were compared to controls (n=10). Different respiratory tract
samples were obtained including both protected specimen brushes (PSBs) and bronchoalveolar lavage
(BAL). The microbiota within the respiratory tract and the macrophage gene expression of the study
participants were investigated. Our aims were to analyse differences in 1) microbiota profiles between the
COPD severity degrees and non-COPD controls, 2) microbiota profiles at distinct sites of the
respiratory tract, 3) macrophage gene expression in COPD patients and controls, and to understand
4) the relationship between altered microbiota and host macrophage phenotype.
Methods
Study design and sample collection
The study was approved by the institutional ethics board of the Canton of Bern, Switzerland. Between
September 2013 and February 2016, participants with stable COPD (n=32) with bronchoscopies indicated
for endoscopic lung volume reduction or suspected lung cancer were enrolled at the University Hospital of
Bern. Details of recruitment of patients and controls as well as exclusion criteria can be found in the
supplementary material. The following respiratory samples were obtained: the pharynx was sampled with
PSBs; the trachea, main bronchus, lobar bronchi (upper, middle and lower on the right side; upper, lingula
and lower lobe on the left side) were sampled during bronchoscopy with PSBs. Brushes were placed in
tubes containing 1.4 mL sterile PBS. BAL was additionally obtained from either the middle lobe or the
lingula as previously published [10]. Particular, state-of-the-art care was taken to minimise contamination
during bronchoscopies as outlined in the supplementary material.
Sample procedures and 16S ribosomal RNA sequencing of the microbiota
DNA extractions were performed for all samples as described in detail previously and outlined in the
supplementary material [11]. The protocols included a very stringent procedure to handle low-density
material that involved the processing of negative controls and the exclusion of samples below a distinct
DNA concentration threshold. This means that samples with <1.0 ng·μL−1 PCR product, corresponding to
<1 pg·μL−1 bacterial DNA, were excluded (see supplementary material). Exclusion of samples from GOLD
3/4 patients was higher as compared to the other groups as bronchoscopy/BAL was more difficult to
perform within these patients (e.g. to receive large quantities of BAL) and, therefore, fewer high-quality
samples were received. BAL samples were additionally utilised for standard bacterial cultures. We also
treated a subset of BAL samples (n=10) with propidium monoazide (PMA) (Biotium, Fremont, CA, USA)
to remove dead bacterial cells before DNA extraction (see supplementary material for more details) in
order to evaluate the consequences of prior PMA treatment for the microbiota results of our samples. PCR
of the V3–V5 region of the 16S ribosomal RNA (rRNA) gene was performed using primer pair 341F/907R.
Sequence reads were analysed using the PyroTagger pipeline, which comprised quality filtering, removal of
chimaeras, the definition of 97% operational taxonomic units (OTUs) and taxonomic assignment as
described and outlined in the supplementary material [12]. Species richness, Shannon Diversity Index
(SDI), and β-diversity were calculated in R version 3.3.0 (www.R-project.org) using the vegan package as
described before and in more detail in the supplementary material [13, 14]. For the within-subject
dissimilarity, the BAL from a subject was compared to all other respiratory samples within that subject.
For the between-subject dissimilarity, the BAL samples from all subjects were compared pairwise. The
project accession number for the sequence reads of this study is PRJEB20508.
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Characterisation of BAL cell gene expression
Macrophages represent the predominant cells recovered by BAL and thus, characterisation of BAL cells
gene expression is mainly a characterisation of macrophage gene expression [15, 16]. Quantitative
real-time PCR was performed for tumour necrosis factor (TNF)-α, CXCL11, cyclo-oxygenase (COX)2,
tissue inhibitor of metalloproteinase 1, platelet-derived growth factor (PDGF)-D, matrix metallopeptidase 12,
dendritic cell-speciﬁc intracellular adhesion molecule-3-grabbing non-integrin (DCSIGN), mannose
receptor C (MRC)1, IL-1 receptor antagonist (IL1RN), IL-10 and indoleamine 2,3-dioxygenase (IDO) with
the following innate immune functions in the BAL samples: inflammation, immunoregulation, scavenging
and remodelling. The characterisation of the BAL cell gene expression was previously described and the
procedure is detailed in the supplementary material [17].
Statistical and correlation analyses
For the PMA treatment analyses, where only two groups were compared, a paired t-test (for normally
distributed data) or a Mann–Whitney test (for not normally distributed data) were performed. For the
other analyses, where more than two groups were compared, two-way ANOVA tests were performed.
Tukey’s multiple comparisons tests were used to correct for the number of sampled sites (n=8) and COPD
status (n=3). Relative abundances of bacterial families were log(Y+1)-transformed as they were not
normally distributed. We analysed both the differences between the different sampling sites and the
differences between patient groups. To test differential host gene expression, the data were log-transformed
and Mann–Whitney tests were applied. In addition, a principal component analysis (PCA) was performed
using prcomp from the stats package (scaled) routine in R. Correlation of macrophage gene expression
markers with SDI and richness was done by Pearson correlation analysis. In addition, we performed
univariate negative binomial regression modelling for the association of host gene expression with the
relative abundances of bacterial families, as the latter were not normally distributed (details and results in
the supplementary material).
Results
Study design, sample collection and quality control
We included a total of 42 participants (10 controls and 32 COPD patients) (table 1). COPD patients were
stratified according to the degree of airflow limitation into patients with mild (GOLD 1) (n=6), moderate
(GOLD 2) (n=8), severe (GOLD 3) (n=8) and very severe COPD (GOLD 4) (n=10). Patient characteristics
are shown in detail in table 1. Patients with more severe airflow limitation (GOLD 3/4) had increased
dyspnoea (modified Medical Research Council dyspnoea score ⩾2), were more symptomatic (COPD
Assessment Test score ⩾10) and exacerbated more than once annually (table 1). In total, 187 samples from
32 COPD patients and 10 controls were analysed (table 1). After 16S rRNA sequencing, 172 (92%)
samples passed all the quality checks (92%) (supplementary material). To achieve more statistical power,
we subsequently grouped COPD GOLD 1 and 2, and GOLD 3 and 4. PMA pre-treatment for the removal
of dead cells in a subset of BAL samples (n=10) did not have a significant effect on the microbiota
composition (figure S1). Results of standard culture of BAL samples are shown in the supplementary
material.
α-diversity values are decreased in GOLD 3/4 patients
We first investigated the α-diversity by calculating the sample richness and the SDI. There was no
difference in species richness between controls and COPD patients, as well as no differences between the
different sampling sites (figure S2A). The SDI, in contrast, was significantly decreased in COPD GOLD 3/4
patients as compared to controls and GOLD 1/2 patients (figure S2B) (two-way ANOVA; compared to
controls: pharynx p=0.01, trachea p=0.02, middle lobe p=0.02 and BAL p<0.0001, respectively; compared
to GOLD 1/2 patients: pharynx p=0.01 and BAL p=0.004, respectively).
COPD patients with early disease (GOLD 1/2) did not show changes in the SDI from normal subjects
and, therefore, changes in SDI were restricted to advanced disease (GOLD 3/4).
Bacterial community comparisons and β-diversity measurements
Overall, COPD GOLD 3/4 patients clustered significantly differently compared to controls and GOLD 1/2
patients illustrated by hierarchical clustering based on bacterial families (figure 1) (permutational
multivariate ANOVA (MANOVA), p=0.001). We observed increased Prevotellaceae and Acidaminococcaceae
within healthy controls, which has been previously shown [18]. However, the bacterial communities are
not significantly separated according to different sites along the respiratory tract (figure 1). We next
investigated more thoroughly the differences in the microbiota along the respiratory tract (i.e. different
sites), performing β-diversity analyses that included analysis based on 97% OTUs rather than bacterial
families (figure 2a–c). With this analysis, we found a significantly different clustering only for the pharynx
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of COPD GOLD 1/2 and GOLD 3/4 patients (figure 2b and c) (permutational MANOVA; p=0.05 and
p=0.04, respectively). We then calculated the dissimilarity between all samples of the respiratory tract
within a subject (within-subject dissimilarity) and compared these values to the dissimilarity between BAL
samples of different subjects (between-subject dissimilarity). There was a significantly lower within-subject
dissimilarity compared to the between-subject dissimilarity in all groups (figure 2d–f ) (Mann–Whitney
tests, p<0.001 for all groups), indicating a more similar microbiota along the respiratory tract of a subject
compared to the microbiota of BAL samples between different subjects. In addition, analysing the
between-subject dissimilarity of the three groups (figure 2d–f ) we found a gradual increase in dissimilarity
by COPD severity degree (Mann–Whitney tests; p<0.0001, p<0.0001 and p=0.004). Therefore, these
findings illustrate a more pronounced microbiota heterogeneity within COPD GOLD 3/4 patients
compared to the controls and to GOLD 1/2 patients.
BAL cell gene expression significantly groups GOLD 3/4 patients
Next, gene expression analyses were performed based on 39 out of 42 BAL samples from COPD patients
and controls (three samples had to be excluded because of insufficient RNA yield). As for inflammatory
markers, the number of CXCL11 gene transcripts increased with COPD severity degree and was highest in
GOLD 3/4 patients (figures 3a–c and S3) (Mann–Whitney test, p=0.01). For immunomodulatory markers,
a higher expression of IDO and IL-10 was seen in COPD GOLD 3/4 compared to controls (p=0.03 for
IDO; p=0.003 for IL-10). Regarding markers for scavenging receptors and remodelling, significantly
TABLE 1 Description of the study participants and the number of samples per group and per
sampling site
Non-COPD
controls
COPD
GOLD 1 GOLD 2 GOLD 3 GOLD 4
Participants 10 6 8 8 10
Male 5 (50.0%) 3 (50.0%) 7 (87.5%) 4 (50.0%) 8 (80.0%)
Age years mean 58.3 68.7 66.9 66.0 62.6
Smoking status
Nonsmoker 3 (30.0%) 2 (33.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Ex-smoker 2 (20.0%) 2 (33.3%) 4 (50.0%) 5 (62.5%) 9 (90.0%)
Active smoker 5 (50.0%) 2 (33.3%) 4 (50.0%) 3 (37.5%) 1 (10.0%)
FEV1# % predicted 95.0±8.5 86.0±4.6 68.3±9.2 36.3±5.1 25.2±4.4
Annual exacerbation rate 0.0±0.0 0.0±0.0 0.5±0.7 1.4±0.7 1.2±1.2
mMRC score 1.0±1.4 1.2±1.1 0.9±0.8 3.3±1.4 3.1±1.2
CAT score 7.5±0.7 7.4±5.4 8.6±3.6 19.6±5.5 17.3±6.9
COPD medication
LABA 0 (0.0%) 0 (0.0%) 2 (25.0%) 1 (12.5%) 2 (20.0%)
LAMA 0 (0.0%) 1 (16.7%) 6 (75.0%) 6 (75.0%) 7 (70.0%)
ICS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
LABA+ICS 2 (20.0%) 2 (33.3%) 3 (37.5%) 7 (87.5%) 9 (90.0%)
LABA+LAMA 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 1 (10.0%)
PDE-4 inhibitor 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%)
Theophylline 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (25.0%) 0 (0.0%)
Total number of samples 62 41 38 19 27
BAL samples for microbiota/gene
expression analysis
10/10 6/6 7/6 3/8 4/9
Lingula 3 2 2 0 1
Lower lobe 8 5 3 2 2
Main bronchus 9 7 4 2 3
Pharynx 10 6 7 8 10
Trachea 9 6 7 2 4
Upper lobe 9 6 5 2 2
Middle lobe 4 3 3 0 1
Data are presented as mean±SD unless otherwise stated. COPD: chronic obstructive pulmonary disease;
GOLD: Global Initiative for Chronic Obstructive Lung Disease; FEV1: forced expiratory volume in 1 s;
mMRC: modified Medical Research Council dyspnoea scale; CAT: COPD Assessment Test; LABA:
long-acting β2-agonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroid; PDE:
phosphodiesterase; BAL: bronchoalveolar lavage. #: post-bronchodilatation.
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reduced gene expression was seen for MRC1 and DCSIGN in COPD GOLD 3/4 patients compared to
both controls (p=0.003 for MRC1; p=0.04 for DCSIGN) and GOLD 1/2 patients (p=0.001 for MRC1;
p=0.0004 for DCSIGN) (figures 3a–c and S3). Overall, gene expression analyses clearly separated GOLD 3/4
patients from controls and GOLD 1/2 patients, as illustrated in the PCA (figure 3d). The data for GOLD
3/4 within the PCA plot are widely scattered, again illustrating increased heterogeneity of the host response
among GOLD 3/4 patients, as compared to the controls and to GOLD 1/2 patients.
Correlation of the BAL cell gene expression and the microbiota
We then performed correlation analysis of BAL cell gene expression results with the paired α-diversity
values SDI and richness (figures 4 and S4). These analyses were independent of the COPD severity
classifications as defined by the clinicians. Pearson correlation revealed a positive association with richness
for COX2 (p=0.01) and MRC1 (p=0.01). In contrast, a negative correlation was found for the SDI and
richness for IL-10 (p=0.02) and IL1RN (p=0.04). Employing a correlation analysis based on bacterial
families of the microbiota, Moraxellaceae were positively correlated with IL-10 (p=0.04), CXCL11
(p=0.04), IDO (p=0.02) and TNF-α (p=0.001), while the opposite was true for Streptococcaceae and
TNF-α (p=0.02) (data not shown).
Integrative analyses of the BAL cell gene expression and the microbiota
However, relative abundances of bacterial families were not normally distributed and we therefore
performed univariate negative binomial regression modelling to investigate associations between the
relative abundance of bacterial families and paired data of the BAL cell gene expression of the host (table S2).
We found a positive association of Flavobacteriaceae and PDGF-D (figure S5 and table S2) (negative
binomial regression model, estimate±SE 0.07±0.03, p=0.03).
Discussion
While there is an increasing body of information on the microbiota and host immune responses in COPD
exacerbation [19–24], data from stable COPD patients are still scarce. Here, we performed a cross-sectional
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FIGURE 1 Bacterial community comparison of samples with the most abundant bacterial families (>0.5% mean relative abundance). Illustrated
are the samples for the upper lobe (UL), middle lobe (ML), lower lobe (LL), main bronchus (mBr), bronchoalveolar lavage (BAL), lingula, trachea
and oropharynx. Samples were grouped according to the site of the respiratory tract and disease status (controls, Global Initiative for Chronic
Obstructive Lung Disease (GOLD) grade 1/2 and GOLD 3/4). The tree was produced with hierarchical clustering (hclust from the stats package in R
using the ward method). Bacterial composition of chronic obstructive pulmonary disease (COPD) GOLD 3/4 patients (mBr, UL, LL, BAL, pharynx
and trachea) differed significantly from samples of controls and GOLD 1/2 patients, as measured by permutational multivariate ANOVA (adonis
function of the vegan package in R) (p=0.001, stress 0.196).
https://doi.org/10.1183/23120541.00015-2018 5
COPD | M. MIKA ET AL.
study of 32 stable COPD patients with different disease severity degrees and compared these to 10
controls. Overall, this is, to the best of our knowledge, the first study investigating the airway microbiota of
different sites of the respiratory tract in COPD patients with different disease severity degrees, in
combination with host immune gene expression data of BAL cells.
In our study, the microbiota composition of COPD patients was mirrored by a decreased abundance of
commensal bacteria, such as the family of Prevotellaceae, which is in line with previous findings from
other studies [1–3, 25] and, together with differences in the β-diversity analyses, clearly demonstrated a
disordered microbiota in patients with COPD. However, despite the GOLD stratification into different
lung functional severity degrees (1–4) and risk classes (A–D), COPD is a highly heterogeneous disease [26, 27].
This is also reflected by our microbial between-subject dissimilarity finding that was most pronounced in
more advanced COPD GOLD 3/4 patients and may suggest that the heterogeneity of the microbiota may
need to be taken into account when defining COPD phenotypes [27].
A major strength of our study is that we also investigated the differences in the microbiota among the
different sampling sites within the respiratory tract. In general, our data indicated a rather homogenous
microbiota along the respiratory tract. This finding is consistent with a previous study by CHARLSON et al. [28]
performed in healthy subjects. In addition, we also hypothesise that bacteria enter the lungs in health
primarily by microaspiration, as previously suggested [29]. Our results somewhat diverge from a study by
ERB-DOWNWARD et al. [2] that described a compartmentalisation of the respiratory tract microbiota in
COPD. In their study, explanted lung tissue was utilised, which may partly account for the differences
observed. Taken together, and excluding the oropharynx with its indeed different profile in COPD
patients, we hypothesise a homogenous microbiota along the respiratory tract of stable patients with
COPD and controls. This may therefore support a more general approach to treating a disordered
microbiota in COPD in the future. However, such a future strategy needs to take into account the
heterogeneity of COPD with exceptions for individual patients and circumstances may differ during
exacerbations.
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from pharynx clustered significantly differently in chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic Obstructive Lung
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A recent study found a correlation between decreased sample diversity in COPD patients and forced
expiratory volume in 1 s (FEV1) as a clinical marker of the disease [1]. Consistent with our data and due
to the fact that COPD is heterogeneous, this suggests that the sample diversity may be employed as a
surrogate marker of the degree of microbiota disordering in COPD, rather than actual bacterial
abundances. Within our study, we correlated sample diversity and richness with the host immune
responses rather than FEV1, offering an additional insight into the pathogenesis of COPD. Not only did
expression of both immunomodulatory IL-10 and scavenging receptor and remodelling marker MRC1
correlate with bacterial diversity or richness, but gene expression was also significantly associated with
more advanced COPD (GOLD 3/4) patients. Comparing the immune stimulatory capacity on human
monocyte-derived dendritic cells of pathogenic Haemophilus spp. and Moraxella spp. revealed that, similar
to our study, the bacteria provoked a higher production of IL-10 compared to other “commensal” bacteria [30].
Regarding the analysis of scavenging receptor and remodelling markers of macrophages, we found
significantly decreased expression of MRC1 and a positive correlation with species richness in COPD
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FIGURE 3 Expression of bronchoalveolar lavage cell markers. The relative abundances of inflammatory (red),
immunomodulatory (blue) and remodelling/scavenging receptor (green) markers are shown. Results are
shown according to a) controls, b) chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic
Obstructive Lung Disease (GOLD) grade 1/2 patients and c) COPD GOLD 3/4 patients. p-values (Mann–Whitney
tests) of GOLD 3/4 patients compared to controls are indicated in (c). In addition, d) principal component
analysis (PCA) based on the selected gene targets is shown. Mean values of the three groups were received
and the highest mean value of each cell marker was set as 100% while the other values are relative means. A
clear separation of GOLD 3/4 patients (3/4) from the controls (0) is illustrated (red surface). Arrows indicate
clustering of samples according to the severity of COPD (i.e. controls (0), COPD GOLD 1/2 (1/2) and COPD
GOLD 3/4 (3/4)). COX: cyclo-oxygenase; TIMP: tissue inhibitor of metalloproteinase; PDGF: platelet-derived
growth factor; MMP: matrix metallopeptidase; DCSIGN: dendritic cell-speciﬁc intracellular adhesion
molecule-3-grabbing non-integrin; MRC: mannose receptor C; IL1RN: interleukin-1 receptor antagonist; IL:
interleukin; IDO: indoleamine 2,3-dioxygenase; TNF: tumour necrosis factor; PC: principal component.
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GOLD 3/4 patients. MADSEN et al. [31] demonstrated in a mouse model that a genetic knockout of the
mannose receptor MRC1 led to impaired intracellular collagen degradation. Collagen degradation is
required for tissue remodelling and repair [31], and disturbed collagen homeostasis might thus indicate a
perturbed homeostasis of tissue repair and degradation in COPD patients. Our study expanded
investigations beyond establishing a mere library of pulmonary microbiota, and provides evidence for
significant correlations between the microbiota and the host immune response. A recent study suggested
that the host immune response to microorganisms in the lung microbiota contributed to the pathogenesis
of GOLD 4 COPD patients [32], and this link was further mechanistically investigated in a COPD mouse
model [33]. Though we now provide the most comprehensive study in the field, together with the other
two studies, we were not able to answer the question of whether the altered gene expression drives the
disordering of the microbiota in COPD or vice versa.
There are limitations to our study. Even though we included a reasonably high number of samples from
COPD patients, the study size still remains a limiting factor for a microbiota study due to the observed
heterogeneity in patients. Based on accurate power analyses [34], more individuals should be included,
although it is challenging to find sufficient volunteers allowing brushing of the respiratory tract at different
sites. However, protected sampling is preferable in bronchoscopic studies of the airway microbiome to
avoid contamination [35]. Furthermore, the groups we compared received different COPD medication,
which has been shown to influence the microbiota composition [4]. Especially for severely and very
severely diseased COPD patients, we found a high between-subject dissimilarity, which indicates a
heterogeneous microbiota composition between the different patients. It is therefore difficult to unravel the
effects of different covariates and the disease itself on the microbiota composition. In order to adjust for
covariates, larger longitudinal studies will be required in the future. A further limitation of our study is the
inclusion of two controls that had received long-acting β2-agonists (LABA) plus inhaled corticosteroids
(ICS) for symptomatic treatment of cough, but without evidence for a respiratory condition. Within this
study, the inclusion of completely healthy controls was challenging due to ethical issues, but neither the
smoking controls nor the participants with LABA+ICS revealed a disordered microbiota as compared to
all the other controls. Finally, since BAL cells were not sorted prior to total RNA isolation, the results
pertain to total BAL cells. Although the set of gene targets that were selected are primarily transcribed in
macrophages, a partial contribution of other cells, especially neutrophils, cannot be excluded.
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FIGURE 4 Correlation of expression values of bronchoalveolar lavage cell markers with α-diversity
measurements: Shannon Diversity Index (SDI) and richness (S). Illustrated are the cell markers with
significant correlations with α-diversity, namely a) cyclo-oxygenase (COX)2, b) mannose receptor C (MRC)1,
c) interleukin (IL)-10 and d) IL-1 receptor antagonist (IL1RN) (p-values are derived from Pearson correlation).
The linear regressions (solid lines) with 95% confidence intervals (dotted lines) are indicated. Only significant
p-values are shown (i.e. p<0.05).
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In conclusion, we showed that the respiratory tract microbiota in COPD patients is disordered when
compared to controls, and is characterised by a lower diversity and a different bacterial composition. The
disordered microbiota is closely associated with an altered macrophage gene expression profile in BAL
cells. These data provide an extensive description of host and microbiota factors in different COPD
severity degrees, and may thus contribute to an improved understanding of factors determining the course
and prognosis of disease in COPD patients.
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